Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259232 | 0.82 | NAMPT (0.54) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6376918 | 0.81 | TP53 (0.63) | KMT2ASMN1; SMN2LMNAEPHX2NPSR1 | |
| SCHEMBL4877647 | 0.80 | SMN1; SMN2 (0.71) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL27577307 | 0.78 | EPHX2 (0.72) | KMT2ASMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL5159206 | 0.76 | SMN1; SMN2 (0.57) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL316042 | 0.76 | SMN1; SMN2 (0.74) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL315111 | 0.76 | NPC1 (0.80) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL5424658 | 0.75 | SMN1; SMN2 (0.56) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL3590338 | 0.74 | SIGMAR1 (0.73) | KMT2AMEN1SMN1; SMN2LMNAPOLB | |
| SCHEMBL4884780 | 0.74 | SMN1; SMN2 (0.62) | KMT2AMEN1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | BRYANS JUSTIN S | 2007-09-27 | — | — | US | disclosed |
| EP-1742932-A1 | 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR | Pfizer Limited (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005105779-A1 | 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | AVPR2, RXFP3, AVPR1A | KMT2A 4644/4885MEN1 2015/4885SMN1; SMN2 2438/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | KMT2A 1922/4885MEN1 476/4885SMN1; SMN2 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.